Stonegate Capital Partners has updated its coverage of Viemed Healthcare, Inc., highlighting the company's substantial growth in fiscal year 2025. Viemed reported a 21% year-over-year increase in net revenue, reaching $270.3 million, alongside net income of $14.9 million and record adjusted EBITDA of $61.4 million. This performance was supported by ongoing platform momentum and contributions from the acquisition of Lehan's, which broadens commercial exposure and diversifies payor mix. The broader industry shift toward in-home care and accelerating adoption of sleep and resupply services provided additional tailwinds.
A key development highlighted is that sleep and resupply services are now overtaking ventilation in Viemed's business, which improves recurring revenue quality and reduces regulatory sensitivity. However, the company faced a short-term headwind from an updated National Coverage Determination that added documentation requirements and tightened coverage criteria for ventilators, temporarily moderating patient growth in that segment. Stonegate notes that reimbursement levels were unchanged and ventilator activity has begun to normalize. Viemed ended the year with free cash flow up 141% year-over-year.
Despite some margin mix pressure, Stonegate's analysis suggests that Viemed's fiscal year 2026 guidance and current valuation indicate that durable growth prospects may remain underappreciated by the market. The firm's full research report, including downloadable images and additional details, is available here. The integration of Lehan's is seen as creating a longer runway for scaled growth by diversifying the company's service offerings and payor base.
The update underscores the evolving landscape of healthcare delivery, where in-home care models are gaining traction. Viemed's strategic positioning within this trend, combined with its financial discipline, positions it to navigate regulatory changes while capitalizing on high-growth segments like sleep therapy and medical equipment resupply. For Texas businesses and investors, Viemed's performance demonstrates how healthcare companies can adapt to regulatory shifts while expanding service lines that meet growing patient demand for home-based care. The company's 141% increase in free cash flow provides resources for further strategic investments in Texas' expanding healthcare sector.
